Clinical Trial Update: CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports the Phase 1 study of CEND-1 in combination with nab-paclitaxel and gemcitabine for metastatic pancreatic cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CEND-1
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Lisata Therapeutics, Inc. | Conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED